Summary

Induced Pluripotent Stem Cells Production Market Summary

The global induced pluripotent stem cells production market size was estimated at USD 1.62 billion in 2024 and is projected to reach USD 3.78 billion by 2033, growing at a CAGR of 10.01% from 2025 to 2033. The potential of stem cell-based therapies, the growing incidence of cancer, capital investments for stem cell-based research, and multiple advantages of induced pluripotent stem cells (iPSCs) over embryonic stem cells (ESCs) are driving the market growth significantly.

Expanding Role of iPSC-Derived Cells in Drug Discovery and Toxicology Screening
The use of induced pluripotent stem cell (iPSC)-derived cells in drug discovery and toxicology screening is emerging as a major growth driver for the iPSC production market. Pharma and biotech companies are increasingly adopting iPSC-derived cardiomyocytes, hepatocytes, and neuronal cells to create physiologically relevant in vitro models that better mimic human biology than conventional cell lines or animal models. These models enable high-throughput screening, improve early-stage safety and efficacy assessments, and align with the global push to reduce animal testing, meeting ethical and regulatory expectations.

Global Induced Pluripotent Stem Cells Production Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global induced pluripotent stem cells production market report based on process, workflow, product, application, end use, and region:

• Process Outlook (Revenue, USD Million, 2021 - 2033)
• Manual iPSC Production Process
• Automated iPSC Production Process
• Workflow Outlook (Revenue, USD Million, 2021 - 2033)
• Reprogramming
• Cell Culture
• Cell Characterization/Analysis
• Engineering
• Others
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Instruments/ Devices
• Automated Platforms
• Consumables & Kits
o Media
o Kits
o Others
• Services
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Drug Development & Discovery
• Regenerative Medicine
• Toxicology Studies
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Research & Academic Institutes
• Biotechnology & Pharmaceutical Companies
• Hospitals & Clinics
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
o U.S.
o Canada
o Mexico
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Denmark
o Sweden
o Norway
• Asia Pacific
o Japan
o China
o India
o Australia
o Thailand
o South Korea
• Latin America
o Brazil
o Argentina
• Middle East and Africa (MEA)
o South Africa
o Saudi Arabia
o UAE
o Kuwait

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.2.1. Process
1.2.2. Workflow
1.2.3. Product
1.2.4. Application
1.2.5. End Use
1.3. Information analysis
1.4. Market formulation & data visualization
1.5. Data validation & publishing
1.6. Information Procurement
1.6.1. Primary Research
1.7. Information or Data Analysis
1.8. Market Formulation & Validation
1.9. Market Model
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Expanding Role of iPSC Derived Cells in Drug Discovery and Toxicology Screening
3.2.1.2. Growing Adoption of iPSC in Personalized and Precision Medicine
3.2.2. Market Restraint Analysis
3.2.2.1. Stringent process control and regulatory challenges
3.2.2.2. High cost of production
3.3. Industry Analysis Tools
3.3.1. Porter's Five Forces Analysis
3.3.2. PESTEL Analysis
Chapter 4. Induced Pluripotent Stem Cells Production Market: Process Business Analysis
4.1. Technology Segment Dashboard
4.2. Global Induced Pluripotent Stem Cells Production Market Process, Movement Analysis
4.3. Global Induced Pluripotent Stem Cells Production Market Size & Trend Analysis, by Process, 2021 to 2033 (USD Million)
4.4. Manual iPSC Production Process
4.4.1. Global Manual iPSC Production Process Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Automated iPSC Production Process
4.5.1. Global Automated iPSC Production Process Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Induced Pluripotent Stem Cells Production Market: Workflow Business Analysis
5.1. Workflow Segment Dashboard
5.2. Global Induced Pluripotent Stem Cells Production Market Workflow Movement Analysis
5.3. Global Induced Pluripotent Stem Cells Production Market Size & Trend Analysis, by Workflow, 2021 to 2033 (USD Million)
5.4. Reprogramming
5.4.1. Global Reprogramming Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Cell Culture
5.5.1. Global Cell Culture Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Cell Characterization/Analysis
5.6.1. Global Cell Characterization/Analysis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7. Engineering
5.7.1. Global Engineering Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.8. Others
5.8.1. Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Induced Pluripotent Stem Cells Production Market: Product Business Analysis
6.1. Product Segment Dashboard
6.2. Global Induced Pluripotent Stem Cells Production Market Product Movement Analysis
6.3. Global Induced Pluripotent Stem Cells Production Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
6.4. Instrument/Devices
6.4.1. Global Instrument/Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Automated Platforms
6.5.1. Global Automated Platforms Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Consumables & Kits
6.6.1. Global Consumables & Kits Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.2. Media
6.6.2.1. Global Media Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.3. Kits
6.6.3.1. Global Kits Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.4. Others
6.6.4.1. Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Services
6.7.1. Global Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Induced Pluripotent Stem Cells Production Market: Application Business Analysis
7.1. Sample Type Segment Dashboard
7.2. Global Induced Pluripotent Stem Cells Production Market Application Movement Analysis
7.3. Global Induced Pluripotent Stem Cells Production Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
7.4. Drug Development and Discovery
7.4.1. Global Drug Development and Discovery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Regenerative Medicine
7.5.1. Global Regenerative Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Toxicology Studies
7.6.1. Global Toxicology Studies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7. Others
7.7.1. Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Induced Pluripotent Stem Cells Production Market: End Use Business Analysis
8.1. End Use Segment Dashboard
8.2. Global Induced Pluripotent Stem Cells Production Market End Use Movement Analysis
8.3. Global Induced Pluripotent Stem Cells Production Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
8.4. Research & Academic Institutes
8.4.1. Global Research & Academic Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5. Biotechnology & Pharmaceutical Companies
8.5.1. Global Biotechnology & Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6. Hospitals & Clinics
8.6.1. Global Hospitals & Clinics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Induced Pluripotent Stem Cells Production Market: Regional Estimates & Trend Analysis by Process, Workflow, Product, Application, & End Use
9.1. Regional Dashboard
9.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
9.3. North America
9.3.1. North America Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.3.2. U.S.
9.3.2.1. Key Country Dynamics
9.3.2.2. Competitive Scenario
9.3.2.3. Regulatory Framework
9.3.2.4. U.S. Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.3.3. Canada
9.3.3.1. Key Country Dynamics
9.3.3.2. Competitive Scenario
9.3.3.3. Regulatory Framework
9.3.3.4. Canada Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.3.4. Mexico
9.3.4.1. Key Country Dynamics
9.3.4.2. Competitive Scenario
9.3.4.3. Regulatory Framework
9.3.4.4. Mexico Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.4. Europe
9.4.1. Europe Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.4.2. UK
9.4.2.1. Key Country Dynamics
9.4.2.2. Competitive Scenario
9.4.2.3. Regulatory Framework
9.4.2.4. UK Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.4.3. Germany
9.4.3.1. Key Country Dynamics
9.4.3.2. Competitive Scenario
9.4.3.3. Regulatory Framework
9.4.3.4. Germany Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.4.4. France
9.4.4.1. Key Country Dynamics
9.4.4.2. Competitive Scenario
9.4.4.3. Regulatory Framework
9.4.4.4. France Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.4.5. Italy
9.4.5.1. Key Country Dynamics
9.4.5.2. Competitive Scenario
9.4.5.3. Regulatory Framework
9.4.5.4. Italy Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.4.6. Spain
9.4.6.1. Key Country Dynamics
9.4.6.2. Competitive Scenario
9.4.6.3. Regulatory Framework
9.4.6.4. Spain Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.4.7. Denmark
9.4.7.1. Key Country Dynamics
9.4.7.2. Competitive Scenario
9.4.7.3. Regulatory Framework
9.4.7.4. Denmark Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.4.8. Sweden
9.4.8.1. Key Country Dynamics
9.4.8.2. Competitive Scenario
9.4.8.3. Regulatory Framework
9.4.8.4. Sweden Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.4.9. Norway
9.4.9.1. Key Country Dynamics
9.4.9.2. Competitive Scenario
9.4.9.3. Regulatory Framework
9.4.9.4. Norway Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.5. Asia Pacific
9.5.1. Asia Pacific Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.5.2. Japan
9.5.2.1. Key Country Dynamics
9.5.2.2. Competitive Scenario
9.5.2.3. Regulatory Framework
9.5.2.4. Japan Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.5.3. China
9.5.3.1. Key Country Dynamics
9.5.3.2. Competitive Scenario
9.5.3.3. Regulatory Framework
9.5.3.4. China Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.5.4. India
9.5.4.1. Key Country Dynamics
9.5.4.2. Competitive Scenario
9.5.4.3. Regulatory Framework
9.5.4.4. India Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.5.5. Australia
9.5.5.1. Key Country Dynamics
9.5.5.2. Competitive Scenario
9.5.5.3. Regulatory Framework
9.5.5.4. Australia Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.5.6. Thailand
9.5.6.1. Key Country Dynamics
9.5.6.2. Competitive Scenario
9.5.6.3. Regulatory Framework
9.5.6.4. Thailand Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.5.7. South Korea
9.5.7.1. Key Country Dynamics
9.5.7.2. Competitive Scenario
9.5.7.3. Regulatory Framework
9.5.7.4. South Korea Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.6. Latin America
9.6.1. Latin America Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.6.2. Brazil
9.6.2.1. Key Country Dynamics
9.6.2.2. Competitive Scenario
9.6.2.3. Regulatory Framework
9.6.2.4. Brazil Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.6.3. Argentina
9.6.3.1. Key Country Dynamics
9.6.3.2. Competitive Scenario
9.6.3.3. Regulatory Framework
9.6.3.4. Argentina Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.7. MEA
9.7.1. MEA Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.7.2. South Africa
9.7.2.1. Key Country Dynamics
9.7.2.2. Competitive Scenario
9.7.2.3. Regulatory Framework
9.7.2.4. South Africa Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.7.3. Saudi Arabia
9.7.3.1. Key Country Dynamics
9.7.3.2. Competitive Scenario
9.7.3.3. Regulatory Framework
9.7.3.4. Saudi Arabia Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.7.4. UAE
9.7.4.1. Key Country Dynamics
9.7.4.2. Competitive Scenario
9.7.4.3. Regulatory Framework
9.7.4.4. UAE Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.7.5. Kuwait
9.7.5.1. Key Country Dynamics
9.7.5.2. Competitive Scenario
9.7.5.3. Regulatory Framework
9.7.5.4. Kuwait Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 10. Competitive Landscape
10.1. Participant Categorization
10.2. Strategy Mapping
10.3. Company Market Position Analysis, 2024
10.4. Participant’s Overview
10.4.1. Lonza
10.4.1.1. Overview
10.4.1.2. Financial Performance
10.4.1.3. Product Benchmarking
10.4.1.4. Strategic Initiatives
10.4.2. Axol Bioscience Ltd.
10.4.2.1. Overview
10.4.2.2. Financial Performance
10.4.2.3. Product Benchmarking
10.4.2.4. Strategic Initiatives
10.4.3. Evotec
10.4.3.1. Overview
10.4.3.2. Financial Performance
10.4.3.3. Product Benchmarking
10.4.3.4. Strategic Initiatives
10.4.4. Hitachi, Ltd.
10.4.4.1. Overview
10.4.4.2. Financial Performance
10.4.4.3. Product Benchmarking
10.4.4.4. Strategic Initiatives
10.4.5. REPROCELL Inc.
10.4.5.1. Overview
10.4.5.2. Financial Performance
10.4.5.3. Product Benchmarking
10.4.5.4. Strategic Initiatives
10.4.6. Merck KGaA
10.4.6.1. Overview
10.4.6.2. Financial Performance
10.4.6.3. Product Benchmarking
10.4.6.4. Strategic Initiatives
10.4.7. Fate Therapeutics
10.4.7.1. Overview
10.4.7.2. Financial Performance
10.4.7.3. Product Benchmarking
10.4.7.4. Strategic Initiatives
10.4.8. Thermo Fisher Scientific, Inc.
10.4.8.1. Overview
10.4.8.2. Financial Performance
10.4.8.3. Product Benchmarking
10.4.8.4. Strategic Initiatives
10.4.9. StemCellsFactory III
10.4.9.1. Overview
10.4.9.2. Financial Performance
10.4.9.3. Product Benchmarking
10.4.9.4. Strategic Initiatives
10.4.10. Applied StemCells, Inc.
10.4.10.1. Overview
10.4.10.2. Financial Performance
10.4.10.3. Product Benchmarking
10.4.10.4. Strategic Initiatives